Relapse odds post tx on triple

[slideman]

Anybody know what the chances for relapse are with Inc after tx? I had my 3 month vl test come back und, and am wondering how many have had their 6 month come back positive. Just trying to reduce some stress!! You would think this would get easier after all we go through. I have almost no sides left, but I still stress out at test time. I have been und since wk 4, and I STILL stress out.

[willbb]

Anybody know what the chances for relapse are with Inc after tx? I had my 3 month vl test come back und,
---------------------------------------------
As you can see from what cando posted..slim to none, and it seems with the advent of the new therapys that SVR may well be now considered  12 weeks vs. 24  
Congrats on this!

Will

[can-do-man]

Not sure if the link is still good but here is the results.

Private messages for answers now?  Why?

http://aasld2008.abstractcentral.com/planner?NEXT_PAGE=ITINERARY_ABS_DET_POP&SESSION_ABSTRACT_ID=332272&ABSTRACT_ID=504907&SESSION_ID=35383&PROGRAM_ID=2214

AASLD 2008 Annual Meeting
ID#  1253
Nov 03 8:00 AM - 5:30 PM
Q07. HCV: Treatment

Assessment of serum HCV RNA at week 12 post-treatment is as relevant as week 24 to predict SVR in patients with chronic hepatitis C treated with Pegylated interferon plus ribavirin
M. Martinot-Peignoux1; M. Ripault2; S. Maylin1; L. Leclere1; N. Boyer2; P. Marcellin2, 1
1. INSERM U773 -CRB3, HOPITAL BEAUJON, Clichy, 92110, France.
2. Service d'Hépatologie, HOPITAL BEAUJON, Clichy, 92110, France.


Sustained Virologic response (SVR), in patients with chronic hepatitis C treated with pegylated interferon alpha (PEG-IFN) + ribavirin (RBV) is defined by undetectable serum HCV RNA at the end of the 24 weeks post-treatment follow-up period. Once achieved SVR is durable.
The aim of our study was to evaluate if 12 weeks post-treatment serum HCV RNA assessment could be as relevant as 24 weeks to identify patients with SVR.
Methods: 137 patients, consecutively treated with standard of care regimens of PEG-IFN alpha 2b + RBV, with an end of treatment response were included in the study. Serum HCV RNA was measured at 12 weeks and 24 weeks, after treatment cessation. A subset group of patients was analyzed 4 weeks after treatment cessation. SVR was defined as undetectable serum HCV RNA at the end of the 24 weeks post-treatment follow-up. Virologic relapse (VR) was defined as reappearance of detectable HCV RNA during the 24 weeks post-treatment follow-up. Serum HCV RNA was measured with the VERSANTR HCV RNA Qualitative Assay (TMA) (Siemmens). We evaluated the positive predictive value (PPV) of an undetectable serum HCV RNA to identify patients with SVR at week 4 and week 12 post-treatment follow-up.
Results. At the end of the 24 weeks-post treatment follow-up 108/137 (79%) of the patients demonstrated a SVR and 29/137 (21%) patients demonstrated a VR. At week 12 post-treatment follow-up serum HCV RNA was undetectable in 108 patients, all were SVR: PPV for SVR was 100%; 100 patients had normal serum alanine aminotransferase (ALT) level 97 were SVR: PPV for SVR was 97% (CI: 95%-99%). In the patients with VR viral load was: 6.56±0.59 and 6.11± 0.59 log copies/ml (ns) at baseline and at week 12 post-treatment, respectively. At week 4 post-treatment follow-up serum HCV RNA measurements were available for 60 patients (11 VR and 49 SVR), serum HCV RNA was undetectable in 51/60 patients, the PPV for SVR was 96% (CI 93.3%-98.7%).
Conclusions. Our results show that the assessment of serum HCV RNA at week 12 post-treatment follow-up (PPV 100% is as effective as week 24 to predict SVR). This result emphasizes that post-treatment follow-up to identify patients with SVR or VR could be shortened to 12 weeks.

[pooh55811]

I sent you a private message so please go to your inbox and it will be there.